Tamtam Try Tamtam free
EssilorLuxottica logo

EssilorLuxottica account plan

Optical lenses and frames

At a glance

EssilorLuxottica makes and sells lenses, frames, smart glasses and eye-care technology, with €28,491m of 2025 revenue and 200,000+ employees.

EssilorLuxottica is a vertically integrated vision care and eyewear group, formed in 2018 from Essilor (lenses) and Luxottica (frames and retail), that designs, manufactures and sells lenses, frames, sunglasses, smart glasses and, increasingly, medical technology. It serves 300,000+ wholesale customers and runs 17,750 stores at end-2025 in more than 150 countries, with brands including Ray-Ban, Oakley, Varilux, Transitions and licences such as Prada and Chanel. FY2025 revenue was €28,491m, +11.2% at constant exchange rates, with adjusted operating profit of €4,459m (15.7% of revenue) and net profit attributable of €2,315m. The group has 200,000+ employees. It is listed on Euronext Paris (CAC 40, Euro Stoxx 50), with Delfin, the Del Vecchio family holding, as parent company holding 32.4% of the capital.

Business units

Strategic priorities

Med-tech transformation
The group is evolving "from a 'traditional' optical leader into a med-tech, science and data-driven company", building clinics, diagnostics and AI eye-care software.
AI glasses with Meta
Extend AI glasses across lifestyle, sport and health; smart-glasses production capacity was being expanded to 10 million units a year by the end of 2025, and a $299 Meta Glasses collection launched in June 2026.
Myopia management
Scale the Stellest platform toward prevention: Stellest received FDA De Novo authorisation in September 2025 and launched in the US in Q4 2025; the myopia portfolio grew 24% in Q2 2026.
AI-native organisation
Demand forecasting, store associate co-pilots and preparation for agentic commerce from 2026, under a Responsible Use of AI policy.
Five-year outlook
Over the next five years, on average and at constant exchange rates, "solid growth" of total revenue with broadly aligned growth of adjusted operating profit.

Latest results

In H1 2026 revenue was €14,818m, up 9.7% at constant exchange rates, with Q2 at +8.7% after +10.8% in Q1 "in a more unsettled macro environment". Adjusted operating profit rose 15.0% at constant FX to €2,751m, an 18.6% margin, helped by better wearables profitability and a net positive tariff impact after the US Supreme Court ruled the 2025 additional tariffs unlawful. Direct to Consumer (€8,001m, +11.4%) outpaced Professional Solutions (€6,817m, +7.8%), and Asia-Pacific grew fastest at +13.4%. Net debt rose to €13.39bn (2.0x EBITDA) after dividends, buybacks and acquisitions. The five-year outlook was unchanged.

Investments and deals

Med-tech and clinic acquisitions
2025 deals included Optegra (70+ eye hospitals and clinics, closed 1 Oct 2025), RetinAI, Cellview Imaging, Espansione and Pulse Audition; Signifeye closed in February 2026. Financial investments net of cash were €911m in 2025.
Retail expansion in Asia and the US
A stake in Top Charoen, Thailand's largest optical chain with almost 2,000 stores, closed 2 April 2026, and Pearle Vision acquired West Point Optical Group (90 centres) in June 2026.
Capex and wearables capacity
Capex was €1,525m (5.4% of revenue) in 2025; wearables capacity was expanded in Dongguan, and the Agordo plant in Italy will host the first wearables production lines from early 2027.
Applied Materials partnership
A long-term joint development agreement signed in June 2026 covers waveguides, adaptive lenses and AR optics, with a collaboration lab in Silicon Valley.
Share buybacks
A buyback of up to 5,000,000 shares started 13 February 2026; €969m was spent on 4,561,701 shares in H1 2026.

Challenges and risks

Tariffs and margin dilution
US tariffs from Q2 2025 and the wearables mix cut the adjusted gross margin to 60.9% in 2025 from 63.5% in 2024.
Big-tech competition in smart eyewear
The URD names big-tech entry into smart eyewear as a top risk; Reuters reported the share price had lost more than 40% since its November record as investors worried about competition.
Legitimacy in med-tech
The URD states the group does not yet have the same expertise and legitimacy in med-tech as in its core business.
Cybersecurity and data privacy
Cybersecurity, IT systems and data privacy are ranked among the most severe risks for a group serving more than half a billion patients and consumers a year.
Geopolitics and rising debt
Middle East tensions weighed on Q2 2026 EMEA wholesale, Mainland China is 4% of revenue, and net debt rose to €13.39bn in H1 2026.

What leadership says

“Our goal is to replace, by simplifying its functions, the current smartphone.”

Francesco Milleri, Chairman and CEO · Il Foglio interview, 2025-04-15

“We were too big to stay confined to this small market”

Francesco Milleri, Chairman and CEO · Remarks at the AGM reported by Reuters, 2026-04-28

“A few big players have made product announcements that generated a lot of interest, but we have not yet seen real competing products on the market.”

Francesco Milleri, Chairman and CEO · Remarks at the AGM reported by Reuters, 2026-04-28

“Only a collaborative model, a network company, can keep leadership in innovation and technology.”

Francesco Milleri, Chairman and CEO · Bloomberg Línea, 2025-10-10

Where a supplier can help

Clinical software and diagnostics
Tied to the med-tech transformation and the stated gap in med-tech legitimacy: clinical systems, imaging, AI diagnostics and regulatory expertise help build out the clinic network.
Wearables components and manufacturing
Tied to the AI glasses priority and wearables capacity investment: optics, display, chip, battery and assembly suppliers serve new lines in Dongguan and Agordo.
Retail AI and agentic commerce
Tied to the AI-native organisation priority: demand forecasting, store associate co-pilots and agentic commerce tools across 19,686 stores and e-commerce.
Cyber security and data privacy
Tied to the cybersecurity and privacy challenge, which grows as clinics and connected glasses add health and personal data.
Integration support for acquired retail and clinics
Tied to the Top Charoen, West Point Optical and clinic acquisitions: post-merger IT, store systems and process integration.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like EssilorLuxottica?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about EssilorLuxottica

What does EssilorLuxottica do?

EssilorLuxottica designs, makes and sells prescription lenses, frames, sunglasses, contact lenses, smart glasses and eye-care instruments, through wholesale to opticians and its own stores and e-commerce. It is building a med-tech business with eye clinics and diagnostics.

What was EssilorLuxottica's revenue in 2025?

FY2025 revenue was €28,491m, +11.2% at constant exchange rates, the first double-digit annual growth in the group's history; adjusted operating profit was €4,459m.

How many employees does EssilorLuxottica have?

The group has 200,000+ employees in more than 150 countries.

Who leads EssilorLuxottica?

Francesco Milleri is Chairman and CEO, and Paul du Saillant is Deputy CEO. Delfin, the Del Vecchio family holding chaired by Milleri, is the parent company.

What is EssilorLuxottica's strategy?

The strategy rests on three pillars: med-tech, wearables and AI through smart eyewear, and the brand portfolio, with a five-year outlook of solid revenue growth at constant exchange rates.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)